服用兽用与人用制剂预防和治疗COVID-19的伊维菌素中毒特征
该研究回顾性分析了俄勒冈中毒中心24周内(2021年8月14日至2022年1月31日)因预防或治疗COVID-19而摄入伊维菌素并就诊的37例中毒病例。患者中位年龄64岁,多为男性,多数住院(21例)或急诊治疗(13例),1例死亡。兽用制剂组摄入剂量更高、意识状态改变发生率更高;慢性摄入组每日剂量较小(13.5 mg)、持续时间长(中位3.8周),毒性较急性摄入轻。
要点
- 37例伊维菌素中毒中,神经毒性30例、胃肠道症状14例、肌肉骨骼主诉7例,1例死亡。
- 兽用制剂组比处方片剂组摄入剂量更高,且意识状态改变发生率更高。
- 慢性摄入者每日剂量13.5 mg、中位持续3.8周,毒性较急性摄入者轻。
- 多数患者住院(21例)或急诊治疗(13例),仅3例门诊处理。
- 中毒多见于60岁以上男性,因超推荐剂量用药所致。
适用人群与场景
- 因预防或治疗COVID-19而摄入伊维菌素并导致就诊的患者,来自俄勒冈中毒中心24周(2021年8月14日至2022年1月31日)的病例。
红旗征与不能漏的情况
- 神经毒性(30例)为最常见临床效应,包括意识状态改变,兽用制剂组发生率更高。
- 1例患者死亡。
研究设计与关键结果
- 回顾性分析37例伊维菌素中毒病例,中位年龄64岁,多数为男性。
- 21例住院,13例急诊治疗,3例门诊治疗,1例死亡。
- 17例摄入兽用制剂,15例摄入处方片剂;23例用于治疗COVID-19,14例用于预防。
- 临床效应:神经毒性30例,胃肠道症状14例,肌肉骨骼主诉7例。
- 兽用制剂组摄入剂量高于处方片剂组,且意识状态改变发生率更高。
- 慢性摄入组每日剂量13.5 mg,中位持续3.8周,毒性较急性摄入组轻。
证据类型、等级与局限
- 证据类型:回顾性分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 急诊/ICU医生应识别伊维菌素中毒的神经毒性表现,尤其是使用兽用制剂或大剂量急性摄入者。
- 对慢性摄入者,即使剂量为典型治疗量(每日13.5 mg),持续数周(中位3.8周)也可能出现较轻毒性。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: US poison control centers reported increased cases of ivermectin toxicity during the COVID-19 pandemic. Previous descriptions of ivermectin toxicity have evaluated heterogeneous groups with a variety of ivermectin sources and dosage patterns. We sought to compare the clinical effects of ivermectin toxicity in patients taking human- vs. veterinary-formulations and acute- vs. chronic-ingestion patterns.
METHODS: We performed a retrospective analysis of cases from the Oregon Poison Center of ivermectin exposures for the prevention or treatment of COVID-19 that resulted in a healthcare visit over a 24-week period (14 August 2021 - 31 January 2022).
RESULTS: We identified 37 cases of ivermectin toxicity. The median age of patients was 64 years, and most patients were male. The majority of patients were hospitalized (21) or treated in an emergency department (13). A minority were treated in an outpatient setting (3) and one patient died. Seventeen ingested veterinary formulations and fifteen ingested prescription tablets. Patients reported taking ivermectin for treatment (23) and prevention (14) of COVID-19. Clinical effects included neurotoxicity (30), gastrointestinal symptoms (14), and musculoskeletal complaints (7). Patients taking veterinary products took higher doses of ivermectin and had higher rates of altered mental status than those taking prescription tablets. Patients taking ivermectin chronically took smaller doses (daily dose of 13.5 mg) over a prolonged period (median 3.8 weeks) and developed toxicity that was milder than those with acute ingestions.
CONCLUSION: Ivermectin toxicity developed in predominantly male patients >60 years old who ingested higher than recommended doses and developed neurologic symptoms. Patients who took a veterinary formulation of ivermectin ingested large single doses or large daily doses for several days and developed rapid onset of neurotoxicity. Patients with chronic toxicity developed milder symptoms and tended to take typical therapeutic doses, but continued therapy for weeks rather than days.
参考来源
- Hoang R, Temple C, Correia MS, et al. Characteristics of ivermectin toxicity in patients taking veterinary and human formulations for the prevention and treatment of COVID-19. Clin Toxicol (Phila). 2022. PMID: 36374218. doi:10.1080/15563650.2022.2134788
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。